You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

mk-4830

Showing 1 - 8 of 8
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tumors Trial in Worldwide (MK-4830, Pembrolizumab, Carboplatin)

Recruiting
  • Neoplasms
  • MK-4830
  • +7 more
  • San Francisco, California
  • +31 more
Dec 23, 2022

High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma Trial in Worldwide (Pembrolizumab, Paclitaxel, Carboplatin)

Recruiting
  • High-grade Serous Ovarian Carcinoma
  • Ovarian Carcinoma
  • Pembrolizumab
  • +5 more
  • Aurora, Colorado
  • +37 more
Jan 19, 2023

Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chuo-ku, Tokyo, Japan
    National Cancer Center Hospital ( Site 3700)
Jan 31, 2023

Esophageal Squamous Cell Carcinoma (ESCC) Trial in Japan, Taiwan (Pembrolizumab, Coformulation favezelimab/pembrolizumab,

Recruiting
  • Esophageal Squamous Cell Carcinoma (ESCC)
  • Pembrolizumab
  • +5 more
  • Milan, Lombardia, Italy
  • +13 more
Jan 3, 2023

Melanoma Trial in Worldwide (Pembrolizumab, Vibostolimab, V937)

Recruiting
  • Melanoma
  • Pembrolizumab
  • +5 more
  • Los Angeles, California
  • +28 more
Jan 25, 2023

Small Cell Lung Cancer Trial in Worldwide (Pembrolizumab, MK-4830, MK-5890)

Recruiting
  • Small Cell Lung Cancer
  • Pembrolizumab
  • +6 more
  • Gilbert, Arizona
  • +48 more
Jan 19, 2023

Carcinoma, Renal Cell Trial in Worldwide (Pembrolizumab, MK-4830, Belzutifan)

Recruiting
  • Carcinoma, Renal Cell
  • Pembrolizumab
  • +5 more
  • New Haven, Connecticut
  • +38 more
Jan 25, 2023

Small Cell Lung Carcinoma Trial in Worldwide (coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830)

Active, not recruiting
  • Small Cell Lung Carcinoma
  • coformulation pembrolizumab/quavonlimab
  • +3 more
  • Gilbert, Arizona
  • +46 more
Jan 2, 2023